Literature DB >> 9704463

Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties.

H J Kolb1.   

Abstract

Allogeneic bone marrow transplantation is an effective treatment of leukemia. Intensive chemo- and radiotherapy used for conditioning and T-cells of the graft contribute to the control of leukemia. Animal experiments indicate that transfusion of lymphocytes from the marrow donor convert into complete chimerism without producing graft-versus-host disease, if delayed for two months or more. Transfusion of donor leukocytes (DLT) after marrow transplantation has induced lasting remissions in the majority of patients with chronic myelogenous leukemia (CML) in hematological or cytogenetic relapse, some patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), transformed phase CML and multiple myeloma (MMY). The mechanism of the graft-versus-leukemia reaction is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704463     DOI: 10.1111/j.1423-0410.1998.tb05438.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  11 in total

Review 1.  Stem cell transplantation.

Authors:  A L Lennard; G H Jackson
Journal:  BMJ       Date:  2000-08-12

2.  Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.

Authors:  Philip H Imus; Amanda L Blackford; Maria Bettinotti; Brian Iglehart; August Dietrich; Noah Tucker; Heather Symons; Kenneth R Cooke; Leo Luznik; Ephraim J Fuchs; Robert A Brodsky; William H Matsui; Carol Ann Huff; Douglas Gladstone; Richard F Ambinder; Ivan M Borrello; Lode J Swinnen; Richard J Jones; Javier Bolaños-Meade
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-25       Impact factor: 5.742

Review 3.  Therapy for childhood acute myeloid leukemia: role of allogeneic bone marrow transplantation.

Authors:  E Abella; Y Ravindranath
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

4.  Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions.

Authors:  Masanori Makita; Yoshinobu Maeda; Katsuto Takenaka; Katsuji Shinagawa; Kazutaka Sunami; Yasushi Hiramatsu; Nobuharu Fujii; Fumihiko Ishimaru; Kazuma Ikeda; Kenji Niiya; Tadashi Yoshino; Mine Harada
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

Review 5.  Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.

Authors:  Christian Sillaber; Matthias Mayerhofer; Hermine Agis; Verena Sagaster; Christine Mannhalter; Wolfgang R Sperr; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

6.  Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.

Authors:  T Ruutu; L C de Wreede; A van Biezen; R Brand; M Mohty; P Dreger; R Duarte; C Peters; L Garderet; S Schönland; A Gratwohl; D Niederwieser; T de Witte; N Kröger
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 7.  Chronic myelogenous leukemia in chronic phase.

Authors:  R Kurzrock; H Kantarjian; M Talpaz
Journal:  Curr Treat Options Oncol       Date:  2001-06

8.  Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.

Authors:  Jutta Auberger; Johannes Clausen; Wolfgang Willenbacher; Martin Erdel; Eberhard Gunsilius; Andreas Petzer; Günther Gastl; David Nachbaur
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

Review 9.  Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.

Authors:  Max Schlaak; Juliane Pickenhain; Sebastian Theurich; Nicole Skoetz; Michael von Bergwelt-Baildon; Peter Kurschat
Journal:  Cochrane Database Syst Rev       Date:  2013-08-29

10.  Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors.

Authors:  E Rådestad; H Wikell; M Engström; E Watz; B Sundberg; S Thunberg; M Uzunel; J Mattsson; M Uhlin
Journal:  J Immunol Res       Date:  2014-10-13       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.